Annovis Bio, Inc.(ANVS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ANVS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Annovis Bio, Inc. (ANVS), a Healthcare sector company. ANVS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Annovis Bio, Inc. reports net income of $-17.6M, free cash flow of $-9.0M. Top institutional holders of ANVS by reported 13-F value include MARSHALL WACE, LLP, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS,, based on the most recent SEC filings. ANVS trades on the NYSE exchange and files with the SEC under CIK 1477845. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Annovis Bio, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-17.6M
Free Cash Flow
Q1 2026
$-9.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+56.2% YoYOperating Income
+40.7% YoYEPS (Diluted)
+62.9% YoYTotal Assets
+36.4% YoYOp. Cash Flow
+45.2% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-24.6M +56.2% | $-56.2M -121.9% | $-25.3M -74.8% | $-14.5M -165.2% | $-5.5M |
| Operating Income | $-26.7M +40.7% | $-45.0M -76.5% | $-25.5M -75.5% | $-14.5M -118.9% | $-6.6M |
| EPS (Diluted) | $-2.31 +62.9% | $-6.23 -101.0% | $-3.10 -63.2% | $-1.90 -118.4% | $-0.87 |
| Total Assets | $13.9M +36.4% | $10.2M -71.7% | $36.0M -21.7% | $46.0M +466.6% | $8.1M |
| Operating Cash Flow | $-21.9M +45.2% | $-40.0M -130.9% | $-17.3M -89.6% | $-9.1M -130.0% | $-4.0M |
AI Insight: ANVS Financial Trends
Pre-revenue biotech burning through equity base with accelerating net losses and negligible cash generation.
• Net loss widened to $18M in Q1 2026 from $6M–$10M range in prior four quarters; operating losses tracking similar deterioration.
• Equity eroded sharply to $3M in Q1 2026 from $24M in Q1 2025—78% decline in one year despite zero revenue.
• Operating cash outflow remains persistent at $3M–$9M per quarter; no pathway to cash generation visible.
⚠ Equity cushion now critically low at $3M; runway likely measured in single-digit quarters at current burn rate.
⚠ Q1 2026 marks steepest loss in dataset; inflection point suggests deteriorating operating conditions or one-time expense impact.
AI Insight: ANVS Ratio Trends
Data too sparse to identify meaningful trends; only two quarters show measurable returns, both deeply negative.
• ROE collapsed to -92.1% in Q1 2025, worsened to -135.7% in Q2 2025, signaling sustained net losses.
• ROA of -82.8% in Q1 2025 indicates asset base is not generating earnings; no subsequent data available.
⚠ Q3 2025, Q4 2025, Q1 2026 show no financial metrics — unclear if data gaps reflect reporting delays or operational status.
Get alerted when ANVS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Annovis Bio, Inc. including:
Top Institutional Holders of ANVS
MARSHALL WACE, LLP
$2.6M1,187,499 shVANGUARD CAPITAL MANAGEMENT LLC
$1.9M872,381 shTWO SIGMA INVESTMENTS, LP
$1.4M627,659 shRENAISSANCE TECHNOLOGIES LLC
$775.1K347,600 shGEODE CAPITAL MANAGEMENT, LLC
$552.2K247,513 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$498.0K223,300 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$486.9K218,336 shNORTHERN TRUST CORP
$316.1K141,730 shBlackRock, Inc.
$311.2K139,533 shVANGUARD FIDUCIARY TRUST CO
$294.5K132,042 sh
| Fund | Value | Shares |
|---|---|---|
| MARSHALL WACE, LLP | $2.6M | 1,187,499 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.9M | 872,381 |
| TWO SIGMA INVESTMENTS, LP | $1.4M | 627,659 |
| RENAISSANCE TECHNOLOGIES LLC | $775.1K | 347,600 |
| GEODE CAPITAL MANAGEMENT, LLC | $552.2K | 247,513 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $498.0K | 223,300 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $486.9K | 218,336 |
| NORTHERN TRUST CORP | $316.1K | 141,730 |
| BlackRock, Inc. | $311.2K | 139,533 |
| VANGUARD FIDUCIARY TRUST CO | $294.5K | 132,042 |
More Healthcare Companies
View all Healthcare →Put ANVS on your watchlist
Track score changes the day Annovis Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANVS a good stock to buy?
13F Pro's AI-powered analysis of Annovis Bio, Inc. (ANVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANVS are available on the ANVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ANVS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Annovis Bio, Inc.'s investment landscape.